Most studies of primary antiretroviral (ARV) resistance have been conducted in large metropolitan areas with reported rates of 8% to 25%. We collected data on 99 HIV-1-infected antiretroviral-naive patients from several sites in Springfield, MA, who underwent genotypic resistance assay between 2004 and 2008. Only major resistance mutations per International AIDS Society-USA (IAS-USA) drug resistance mutations list were considered. The prevalence of resistance was 5% (5 of 99). Three patients had one nonnucleoside reverse transcriptase inhibitor (NNRTI) mutation: 103N, 103N, and 190A, 1 patient had a protease inhibitor (PI) mutation: 90M; and 1 patient had 3-class resistance with NNRTI: 181C, 190A, PI: 90M, and nucleoside analogue reverse transcriptase inhibitor (NRTI): 41L, 210W. Mean time from HIV diagnosis to resistance testing was shorter in patients with resistance versus those without: 9 (range 0.3-42 months) versus 27 (range 0.1-418 months), P ¼ .11. There was a trend to lower mean CD4 count in those with resistance, 170 versus 318 cells/mm 3 , P ¼ .06. No differences were noted in gender, age, HIV risk category, or HIV RNA level. The low prevalence of primary resistance may be explained by differences in demographic and risk factors or may reflect the time from infection to resistance testing. Our findings emphasize the importance of continued resistance surveillance.
Introduction
The prevalence of primary (transmitted) resistance in HIVinfected individuals with undetermined duration of infection has been most recently reported in the range from 8% to 25%. [1] [2] [3] [4] [5] [6] [7] [8] Resistance testing for chronically HIV-infected individuals is currently recommended at the time of the first evaluation and at treatment initiation. 9 The prevalence of primary resistance varies by geographic region and may be influenced by local demographics, HIV risk factors, and the penetration of antiretroviral therapy (ART) in the local area. 9 Relatively few studies have been conducted outside large metropolitan areas where the prevalence and/or patterns of resistance may be different. Knowledge of local resistance data may help to follow trends in the prevalence of resistance and result in a better understanding of the current HIV epidemic.
Methods
HIV-1-infected antiretroviral-naive patients from the HIV clinics affiliated with Baystate Medical Center and 2 private infectious diseases practices, all in Springfield, MA, were enrolled in the study. Springfield is the third largest city in Massachusetts with a population of 148 136. 10 The data were collected retrospectively and prospectively. Only patients who had records of genotypic resistance testing were included in the analysis. Demographic, clinical, and laboratory data were collected using a standardized data collection form. .
Genotypic resistance tests, which were obtained as part of routine care, were performed from January 2004 through April 2008. HIV resistance tests used included HIV GenoSure (Lab-Corp, Research Triangle Park, NC), HIV-1 genotyping for drug resistance (Quest Diagnostics Nichols Institute, Cambridge, MA), and TRUGENE HIV-1 genotyping kit (Visible Genetics, Suwanee, GA) resistance assays.
Mutations were classified based on the International AIDS Society-USA (IAS-USA) drug resistance mutations list. Only mutations sufficient on their own to confer partial resistance, and listed in boldface in the mutation list, were included in the analysis. 11 Patients with resistance mutations were compared to patients without resistance mutations using the 2-tailed t test for continuous variables (Microsoft Excel version 2008) and chi-square or Fishers exact test for categorical variables (Statview for Window, version 5.0.1, SAS Institute, Cary, NC). The study was approved by the Baystate Medical Center Institutional Review Board.
Results
We identified 118 treatment-naive patients who were seen in Springfield HIV clinics during the study period. Of them, 99 underwent genotypic resistance testing. Nineteen patients were started on ART without HIV resistance testing. Demographic and clinical information on 99 patients who had genotypicresistance evaluation are shown in Table 1 .
Approximately two thirds were male. Forty percent of patients were Hispanic followed by Caucasian and African American in approximately equal proportions. The most common mode of HIV acquisition was heterosexual sex, followed by male-male sex, and injecting drug use. The median time after HIV diagnosis to resistance testing was 2 months. The mean HIV RNA at the time of resistance testing was 4.69 log copies/mL and 42% of patients had HIV RNA greater than 100,000 copies/mL. The mean CD4 count was 310 cells/mm 3 and 42% of patients had a CD4 count less than 200 cells/mm 3 .
Five patients were identified with major resistance mutations. All mutations (major and minor) are listed in Table 2 . Three patients each had 1 major mutation associated with resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs): 103N, 103N, and 190A, respectively. The patient with 190A mutation also had 103S mutation. 103S is not considered a major mutation according to the IAS-USA drug resistance mutations list, but according to Stanford University HIV Drug Resistance Data base, 103S confers a high level NNRTIassociated resistance. 12 One patient had a mutation associated with resistance to protease inhibitors (PIs): 90M. The fifth patient had multiclass resistance with 2 NNRTI mutations: 181C and 190A, 1 PI mutation: 90M, and 2 nucleoside reverse transcriptase inhibitor (NRTIs) mutations: 41L and 210W. In addition, 1 patient had a 215C/N/S/Y mutation which may represent a reversion mutation from 215Y/F. 13, 14 Per the IAS-USA drug-resistance mutations list this mutation was not counted as a major resistance mutation.
Demographic and clinical data comparing patients with and without primary resistance mutations are shown in Table 3 . No statistically significant differences were observed in demographic characteristics, HIV RNA, or CD4 counts. There was, however, a trend toward lower CD4 counts among patients with primary resistance mutations. The time between HIV diagnosis and resistance assay was shorter for patients with resistance mutations, but it did not reach statistical significance. Table 4 compares our data with other recent US studies documenting primary resistance in chronically infected patients. Our study had the lowest rate (5%) among these recent studies [1] [2] [3] [4] 6, 7 in which the rate of resistance ranged from 8% to 18%. The distribution of resistance among the antiretroviral classes was consistent with the recently published data, which showed that NNRTI resistance prevalence was the highest, followed by NRTI and PI resistance.
Discussion
The prevalence of ART-associated drug resistance mutations among ART-naive individuals in the United States has varied from 8% to 25% in prior reports. [1] [2] [3] [4] [5] 15 Transmitted resistance assumes acquisition from a patient with resistant virus, which was most likely acquired following exposure of the source patient to ART. Thus, a major determinant of the prevalence of ART-associated mutations is access of the population to ART. For this reason, in some developing countries [16] [17] [18] primary resistance is as low as 1% to 1.5%. The rate of resistance 1-4,6,7 appears slightly lower among individuals with uncertain time of infection and varies from 8% to 10.8%. The prevalence of NNRTI-associated mutation has been increasing and the prevalence of NRTI mutations has been diminishing over the last decade, which is a likely consequence of the increased use of NNRTIs in practice and the low genetic barrier to NNRTI resistance. In addition, the fact that NNRTI mutations have minimal impact on replication capacity may result in longer persistence of NNRTI mutations. It has been estimated that the wild-type virus had less than a 1.5% fitness advantage compared to the K103N NNRTI-resistant variant. 19 Most studies of primary resistance prevalence have been performed in highly populated urban areas. In a recent study 7 from a less populous city in the United States (Wilmington, DE) the primary resistance rate was 8%. Of note, the study included the 98G and 179D mutations. These mutations can potentially confer low level resistance to NNRTIs but according to IAS-USA mutation list they are not considered among mutations independently leading to resistance. Without counting 98G and 179D mutations the resistance prevalence in the study would have been 6%. Another publication on primary resistance outside large cities was presented from North Carolina. The authors reported the resistance prevalence of 17.8%, but they included both acutely and recently infected patients. The likelihood of primary resistance in newly infected patients is likely to be higher than in patients of unknown duration due to reversion of primary mutations in the absence of ongoing antiretroviral ''drug pressure.'' 2, 20 Our study demonstrated a low prevalence of primary ARTassociated drug resistance mutations (5%) compared to the recently published data (Table 4 ). One possible explanation for the low prevalence of primary resistance in our study could be a delay in HIV diagnosis. It has been shown that transmitted drug resistance is most commonly identified among recently infected individuals. 21 However, the levels of CD4 cells in our group, which can be used as surrogates to assess the duration of HIV infection, were comparable with those in other studies of chronically infected patients. In addition, as noted above, some mutations for example, NNRTI mutations can persist for prolonged duration. Thus, reversion to wild-type version prior to resistance testing may not necessarily explain our findings.
Another possible explanation for the low prevalence of transmitted resistance in our cohort is the demographic features of our group. In comparison with patients from other areas of the United States, our population has a higher prevalence of Hispanics, a lower prevalence of African Americans, a higher percentage of intravenous drug users, and lower prevalence of men who have sex with men (Table 4) . A recent publication from Canada evaluating primary drug resistance in chronically HIV-infected antiretroviral-naive injection drug users identified resistance in only in 4.7% of cases. The authors explained the low prevalence of resistance by the likely limited prior exposure of injecting drug uses (IDUs) to antiretroviral medications, which is caused by difficulties in accessing them and a lower likelihood of prescribing ART to drug users. 22 Of note, none of our patients who acquired HIV via intravenous drug use had primary resistance mutations.
Similarly, Hispanics, who represent the major ethnic group in our HIV population, may have limited access to health care due to language and cultural barriers or other socioeconomic factors. This could result in relatively low exposure to ART and subsequently a lower prevalence of transmitted resistance. Although Hispanics did represent 80% of patients with primary resistance in our cohort the numbers are too small to form any conclusions and are not significant. Finally, the relatively low prevalence of resistance in our study might also possibly reflect a trend in decreasing of primary HIV-resistance prevalence or overall lower prevalence of resistance in chronically infected individuals in smaller metropolitan areas of the United States.
Our study has limitations. The sample size was relatively small. Data were collected both retrospectively and prospectively. Resistance testing was not done routinely during the early part of the study because it was not the standard of care at that time. Resistance testing was performed at variable times following HIV diagnosis. Although we have data on time from HIV testing to resistance testing, we do not have data on date of HIV infection, which may have lead to underestimating resistance due to not detecting archived mutations. However, in clinical practice it is rare to have specific HIV infection dates. Thus, our methods are applicable to most practice settings in which resistance testing is performed after patients enter care.
Our findings of a low prevalence of primary antiretroviral resistance reinforce the value of continued resistance surveillance. Knowledge of local demographic data can help in understanding future trends in the ongoing HIV epidemic.
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